Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.05
AGN's Cash to Debt is ranked lower than
97% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. AGN: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
AGN' s 10-Year Cash to Debt Range
Min: 0.02  Med: 0.59 Max: 43.62
Current: 0.05
0.02
43.62
Equity to Asset 0.51
AGN's Equity to Asset is ranked lower than
67% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. AGN: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
AGN' s 10-Year Equity to Asset Range
Min: 0.25  Med: 0.63 Max: 0.93
Current: 0.51
0.25
0.93
F-Score: 3
Z-Score: 1.22
M-Score: -1.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -12.28
AGN's Operating margin (%) is ranked lower than
82% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. AGN: -12.28 )
Ranked among companies with meaningful Operating margin (%) only.
AGN' s 10-Year Operating margin (%) Range
Min: -21.33  Med: 13.94 Max: 37.1
Current: -12.28
-21.33
37.1
Net-margin (%) -15.29
AGN's Net-margin (%) is ranked lower than
83% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. AGN: -15.29 )
Ranked among companies with meaningful Net-margin (%) only.
AGN' s 10-Year Net-margin (%) Range
Min: -22.48  Med: 9.27 Max: 35.15
Current: -15.29
-22.48
35.15
ROE (%) -7.63
AGN's ROE (%) is ranked lower than
76% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. AGN: -7.63 )
Ranked among companies with meaningful ROE (%) only.
AGN' s 10-Year ROE (%) Range
Min: -23.54  Med: 7.99 Max: 22.08
Current: -7.63
-23.54
22.08
ROA (%) -3.81
AGN's ROA (%) is ranked lower than
75% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AGN: -3.81 )
Ranked among companies with meaningful ROA (%) only.
AGN' s 10-Year ROA (%) Range
Min: -13.02  Med: 4.60 Max: 19.77
Current: -3.81
-13.02
19.77
ROC (Joel Greenblatt) (%) -53.21
AGN's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. AGN: -53.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -37.89  Med: 32.56 Max: 107.33
Current: -53.21
-37.89
107.33
Revenue Growth (3Y)(%) 17.90
AGN's Revenue Growth (3Y)(%) is ranked higher than
77% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. AGN: 17.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 6.4  Med: 17.60 Max: 40.5
Current: 17.9
6.4
40.5
EBITDA Growth (3Y)(%) -3.70
AGN's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. AGN: -3.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.4  Med: 7.60 Max: 52.9
Current: -3.7
-4.4
52.9
» AGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

AGN Guru Trades in Q3 2014

Larry Robbins 1,717,858 sh (New)
Dodge & Cox 4,025 sh (New)
Joel Greenblatt 8,180 sh (New)
Bernard Horn 20,689 sh (New)
Steven Cohen 102,900 sh (+311.60%)
John Paulson 1,062,200 sh (+254.07%)
Andreas Halvorsen 2,279,736 sh (+183.77%)
Vanguard Health Care Fund 8,555,596 sh (+154.66%)
George Soros 149,885 sh (+134.82%)
Andreas Halvorsen 2,550,336 sh (+111.15%)
Eric Mindich 1,683,251 sh (+86.82%)
Mario Gabelli 58,056 sh (+60.53%)
Eric Mindich 859,000 sh (+24.13%)
Daniel Loeb 2,875,000 sh (+15.00%)
Leon Cooperman 706,472 sh (+13.96%)
First Eagle Investment 740,675 sh (+4.79%)
Pioneer Investments 139,359 sh (unchged)
Steve Mandel 2,478,628 sh (unchged)
Pioneer Investments 838,740 sh (unchged)
Bill Ackman 28,878,538 sh (unchged)
John Griffin 1,735,000 sh (unchged)
Bill Ackman 28,878,638 sh (unchged)
Ken Heebner Sold Out
Richard Perry Sold Out
Kyle Bass Sold Out
Paul Singer Sold Out
Paul Tudor Jones 101,193 sh (-0.30%)
Ken Fisher 6,015 sh (-2.72%)
Private Capital 167,468 sh (-2.80%)
John Paulson 5,377,200 sh (-4.01%)
Jana Partners 2,514,701 sh (-5.26%)
Mario Gabelli 123,938 sh (-5.53%)
Jeremy Grantham 900,754 sh (-7.43%)
Scott Black 45,177 sh (-7.53%)
Dodge & Cox 3,264 sh (-8.42%)
Paul Tudor Jones 2,300 sh (-20.69%)
Steven Cohen 274,900 sh (-26.00%)
RS Investment Management 550,630 sh (-34.87%)
Louis Moore Bacon 28,636 sh (-39.52%)
Louis Moore Bacon 31,870 sh (-46.88%)
Jim Simons 193,595 sh (-53.51%)
Joel Greenblatt 5,670 sh (-65.17%)
Jim Chanos 15,330 sh (-66.16%)
First Eagle Investment 10,000 sh (-66.67%)
Jim Simons 128,162 sh (-74.76%)
» More
Q4 2014

AGN Guru Trades in Q4 2014

Paul Singer 992,887 sh (New)
Larry Robbins 629,647 sh (New)
George Soros 494,786 sh (New)
Daniel Loeb 400,000 sh (New)
Diamond Hill Capital 2,966 sh (New)
First Eagle Investment 634,476 sh (+6244.76%)
Jim Simons 454,162 sh (+254.37%)
Paul Tudor Jones 6,797 sh (+195.52%)
George Soros 321,214 sh (+114.31%)
Andreas Halvorsen 4,585,892 sh (+79.82%)
Jeremy Grantham 1,464,872 sh (+62.63%)
First Eagle Investment 1,176,582 sh (+58.85%)
Jim Simons 297,860 sh (+53.86%)
John Paulson 1,560,601 sh (+46.92%)
Leon Cooperman 943,572 sh (+33.56%)
Daniel Loeb 3,450,000 sh (+20.00%)
John Paulson 6,370,000 sh (+18.46%)
Larry Robbins 1,841,869 sh (+7.22%)
Pioneer Investments 887,293 sh (+5.79%)
Vanguard Health Care Fund 8,795,896 sh (+2.81%)
Eric Mindich 1,705,933 sh (+1.35%)
First Eagle Investment 60 sh (unchged)
Dodge & Cox 3,264 sh (unchged)
Bernard Horn 20,689 sh (unchged)
Bill Ackman 26,635,978 sh (unchged)
Bill Ackman 26,635,978 sh (unchged)
Joel Greenblatt Sold Out
Steve Mandel Sold Out
Jim Chanos Sold Out
Ken Fisher 5,972 sh (-0.71%)
Private Capital 166,197 sh (-0.76%)
John Griffin 1,625,000 sh (-6.34%)
Bill Ackman 26,635,978 sh (-7.77%)
Scott Black 41,091 sh (-9.04%)
Andreas Halvorsen 1,966,112 sh (-13.76%)
Dodge & Cox 3,293 sh (-18.19%)
RS Investment Management 414,013 sh (-24.81%)
Pioneer Investments 96,064 sh (-31.07%)
Jana Partners 1,718,804 sh (-31.65%)
Mario Gabelli 69,780 sh (-43.70%)
Louis Moore Bacon 16,374 sh (-48.62%)
Mario Gabelli 26,890 sh (-53.68%)
Eric Mindich 332,850 sh (-61.25%)
Louis Moore Bacon 7,666 sh (-73.23%)
Joel Greenblatt 945 sh (-83.33%)
Steven Cohen 21,900 sh (-92.03%)
Paul Tudor Jones 2,700 sh (-97.33%)
Steven Cohen 1,500 sh (-98.54%)
» More
Q1 2015

AGN Guru Trades in Q1 2015

Steve Mandel 1,832,314 sh (New)
Jeremy Grantham 263,619 sh (New)
Ken Fisher 3,233 sh (New)
Bill Ackman 1,348,358 sh (New)
Lee Ainslie 316,188 sh (New)
Julian Robertson 72,500 sh (New)
Signature Select Canadian Fund 10,600 sh (New)
Pioneer Investments 592,904 sh (+517.20%)
Louis Moore Bacon 31,216 sh (+307.20%)
John Paulson 5,640,788 sh (+261.45%)
Steven Cohen 3,783 sh (+152.20%)
Diamond Hill Capital 4,100 sh (+38.23%)
First Eagle Investment 1,573,572 sh (+33.74%)
Andreas Halvorsen 6,105,536 sh (+33.14%)
Mario Gabelli 35,151 sh (+30.72%)
George Soros 417,367 sh (+29.93%)
Larry Robbins 1,982,709 sh (+7.65%)
Daniel Loeb 3,575,000 sh (+3.62%)
Daniel Loeb 3,575,000 sh (+3.62%)
Vanguard Health Care Fund 9,038,107 sh (+2.75%)
Bernard Horn 20,689 sh (unchged)
Mario Gabelli Sold Out
Ken Fisher Sold Out
First Eagle Investment Sold Out
Jeremy Grantham Sold Out
Pioneer Investments Sold Out
Dodge & Cox Sold Out
Jim Simons Sold Out
Bill Ackman Sold Out
John Paulson Sold Out
Steven Cohen Sold Out
George Soros Sold Out
Paul Singer Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Andreas Halvorsen Sold Out
Larry Robbins Sold Out
Eric Mindich Sold Out
Eric Mindich Sold Out
Louis Moore Bacon Sold Out
Daniel Loeb Sold Out
Jim Simons Sold Out
Bill Ackman Sold Out
Leon Cooperman 933,475 sh (-1.07%)
Scott Black 39,451 sh (-3.99%)
Private Capital 158,852 sh (-4.42%)
Jana Partners 1,621,852 sh (-5.64%)
RS Investment Management 385,566 sh (-6.87%)
John Griffin 1,466,000 sh (-9.78%)
Paul Tudor Jones 2,200 sh (-18.52%)
Dodge & Cox 1,602 sh (-51.35%)
» More
Q2 2015

AGN Guru Trades in Q2 2015

Ken Fisher 3,580 sh (+10.73%)
Vanguard Health Care Fund 9,038,107 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA1114.901.225 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Top Ranked Articles about Allergan PLC

Julian Robertson Adds 16 New Stakes to Portfolio
As the founder of one of the earliest hedge funds, Julian Robertson (Trades, Portfolio) is a pioneer in the world of investing. Robertson made 16 new buys in the first quarter, two of which were significant enough to join the 10 most valuable stakes in his portfolio. Now retired, Robertson invests in hedge funds that are often run by his former employees. Read more...
Pioneer Investments Sells Stakes in Allergan, Xilinx in First Quarter
On its website, Pioneer Investments (Trades, Portfolio) assures visitors that its goal is “to offer concrete investment solutions that satisfy real investment needs,” and it claims that its “time-tested” approach to investing “is supported by in-depth research and analysis as well as expert portfolio and risk management.” Read more...
Ruane, Cunniff & Goldfarb Inc Comments on Valeant
A topic many shareholders and clients wanted to discuss with us in 2014 was Valeant (VRX). It is the largest holding in Sequoia by far. One could argue Valeant wasted much of the year on a quixotic effort to buy Allergan (AGN), maker of Botox. Allergan had no interest in being acquired and fought a vicious and savvy public relations campaign to portray Valeant as unworthy of marriage to such a prized catch. In the end, Allergan found a suitor more to its liking in Actavis (ACT), and Actavis agreed to pay a substantially higher price than Valeant had offered. Read more...
Ackman's Pershing Square Now Available To The Public
Bill Ackman’s Pershing Square Holdings started trading on the Euronext Amsterdam under the symbol “PSH” on October 13. Daniel Loeb had a similar IPO in 2007 on the London Stock Exchange with his fund, Third Point Offshore (LSE:TPOU, LSE:TPOG, TPNTF). The goal of the IPO is to raise permanent capital to help the activist investor maintain his positions in target companies during times of turbulence. If too many investors have redemption requests in the hedge fund, the manager will not be able to maintain a position of control over all of the companies in the portfolio. Read more...
Bill Ackman's Midas Touch
Outside the investment community, the name of Bill Ackman (Trades, Portfolio) of Pershing Square might not raise as many eyebrows as the name of a guru like Warren Buffett (Trades, Portfolio), but Ackman’s track record is still impressive. He seems to have the Midas touch, even more of one than many of the gurus followed by GuruFocus. Read more...

Ratios

vs
industry
vs
history
Forward P/E 16.42
AGN's Forward P/E is ranked higher than
82% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. AGN: 16.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.95
AGN's P/B is ranked higher than
73% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. AGN: 1.95 )
Ranked among companies with meaningful P/B only.
AGN' s 10-Year P/B Range
Min: 1.03  Med: 1.76 Max: 5.9
Current: 1.95
1.03
5.9
P/S 5.61
AGN's P/S is ranked lower than
65% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. AGN: 5.61 )
Ranked among companies with meaningful P/S only.
AGN' s 10-Year P/S Range
Min: 0.99  Med: 1.84 Max: 5.61
Current: 5.61
0.99
5.61
PFCF 41.03
AGN's PFCF is ranked higher than
59% of the 275 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.38 vs. AGN: 41.03 )
Ranked among companies with meaningful PFCF only.
AGN' s 10-Year PFCF Range
Min: 6.64  Med: 14.17 Max: 46.2
Current: 41.03
6.64
46.2
POCF 34.75
AGN's POCF is ranked lower than
53% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. AGN: 34.75 )
Ranked among companies with meaningful POCF only.
AGN' s 10-Year POCF Range
Min: 5.97  Med: 11.78 Max: 34.75
Current: 34.75
5.97
34.75
EV-to-EBIT -86.16
AGN's EV-to-EBIT is ranked lower than
180% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. AGN: -86.16 )
Ranked among companies with meaningful EV-to-EBIT only.
AGN' s 10-Year EV-to-EBIT Range
Min: -264.2  Med: 14.10 Max: 145.1
Current: -86.16
-264.2
145.1
Current Ratio 1.44
AGN's Current Ratio is ranked lower than
73% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. AGN: 1.44 )
Ranked among companies with meaningful Current Ratio only.
AGN' s 10-Year Current Ratio Range
Min: 1.31  Med: 2.93 Max: 9.8
Current: 1.44
1.31
9.8
Quick Ratio 1.03
AGN's Quick Ratio is ranked lower than
74% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. AGN: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
AGN' s 10-Year Quick Ratio Range
Min: 0.78  Med: 2.04 Max: 8.82
Current: 1.03
0.78
8.82
Days Inventory 121.45
AGN's Days Inventory is ranked lower than
54% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. AGN: 121.45 )
Ranked among companies with meaningful Days Inventory only.
AGN' s 10-Year Days Inventory Range
Min: 107.12  Med: 128.32 Max: 216.83
Current: 121.45
107.12
216.83
Days Sales Outstanding 99.54
AGN's Days Sales Outstanding is ranked lower than
69% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. AGN: 99.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGN' s 10-Year Days Sales Outstanding Range
Min: 38.55  Med: 58.25 Max: 103.03
Current: 99.54
38.55
103.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.09
AGN's Dividend Yield is ranked lower than
98% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. AGN: 0.09 )
Ranked among companies with meaningful Dividend Yield only.
AGN' s 10-Year Dividend Yield Range
Min: 0.08  Med: 0.32 Max: 0.63
Current: 0.09
0.08
0.63
Yield on cost (5-Year) 0.09
AGN's Yield on cost (5-Year) is ranked lower than
98% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. AGN: 0.09 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.08  Med: 0.32 Max: 0.63
Current: 0.09
0.08
0.63
Share Buyback Rate -20.20
AGN's Share Buyback Rate is ranked lower than
84% of the 463 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.00 vs. AGN: -20.20 )
Ranked among companies with meaningful Share Buyback Rate only.
AGN' s 10-Year Share Buyback Rate Range
Min: 5.5  Med: -3.30 Max: -20.2
Current: -20.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.38
AGN's Price/Projected FCF is ranked higher than
85% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. AGN: 1.38 )
Ranked among companies with meaningful Price/Projected FCF only.
AGN' s 10-Year Price/Projected FCF Range
Min: 0.59  Med: 1.13 Max: 3.29
Current: 1.38
0.59
3.29
Price/Median PS Value 3.05
AGN's Price/Median PS Value is ranked lower than
85% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. AGN: 3.05 )
Ranked among companies with meaningful Price/Median PS Value only.
AGN' s 10-Year Price/Median PS Value Range
Min: 0.67  Med: 1.35 Max: 5.39
Current: 3.05
0.67
5.39
Earnings Yield (Greenblatt) (%) -1.20
AGN's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. AGN: -1.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.7  Med: 6.50 Max: 11.4
Current: -1.2
0.7
11.4
Forward Rate of Return (Yacktman) (%) 8.58
AGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. AGN: 8.58 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AGN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -3.7  Med: 7.95 Max: 16.5
Current: 8.58
-3.7
16.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, FRX, MRX, ESALF » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.
» More Articles for AGN

Headlines

Articles On GuruFocus.com
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
Pennsylvania Trust Co. Top Buys in Q2 2015 Jul 16 2015 
John Griffin Shows Stake in Trendy Fitbit Inc. Jun 30 2015 
Acquisition in the Health Care Industry Increased Volatility Jun 27 2015 
Julian Robertson Adds 16 New Stakes to Portfolio Jun 23 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
Leon Cooperman's Top Holdings Look Attractive Jun 09 2015 

More From Other Websites
Einhorn's Greenlight sees red in July Aug 01 2015
Allergan is Cramer's Favorite Stock, Teva Deal Was 'Incredible' Aug 01 2015
IBD 50: 10 Top Stocks Reporting Earnings This Week Aug 01 2015
Zeltiq Hits New High After Raising Guidance Again Jul 31 2015
The most loved stocks are... Jul 31 2015
Teva Proves Its Decade-Hold Status With Massive Funding Jul 31 2015
Israel ETFs Surge on Teva Megamerger Deal (revised) - ETF News And Commentary Jul 31 2015
Teva Pharmaceutical (TEVA) Earnings Report: Q2 2015 Conference Call Transcript Jul 30 2015
Buy Allergan as emerging aesthetics drug pure play Jul 30 2015
From Actavis to Allergan: One pharma company’s wild dealmaking journey Jul 30 2015
Ackman ‘Wolf Pack' Sent Allergan to Foreigners, Ex-CEO Says Jul 30 2015
Former Allergan CEO is still going after Pershing Jul 30 2015
Ackman’s ‘Wolf Pack’ Sent Allergan to Foreign Hands, Ex-CEO Says Jul 30 2015
Senate Uses Valeant Pharma, Burger King, AB InBev To Expose Unequal Corporate Taxation In U.S. Jul 30 2015
Allergan Confirms Generic Tyvaso® Patent Challenge Jul 30 2015
Valeant Tells Congress a Very Different Tax Tale Than Investors Jul 29 2015
Mylan gets European clearance in proposed Perrigo takeover Jul 29 2015
Mylan gets European clearance in proposed Perrigo takeover Jul 29 2015
5 Stocks With Notable Short-Selling Activity Jul 29 2015
RBC Says Stay Away From Mylan, Perrigo; Go Long Teva, Allergan Jul 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK